TVGN

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is a clinical-stage biotechnology company founded in 2021 and based in Warren, New Jersey. The company went public in January 2022 and specializes in developing off-the-shelf precision T cell therapeutics targeting diseases in virology, oncology, and neurology. Tevogen represents a relatively new entrant in the immunotherapy space, focusing on creating standardized T cell treatments that can be manufactured at scale and administered to patients without the need for personalized cell engineering.